Winter Congress Virtual Booth
Although we are disappointed that we can’t meet you in person, we are excited to welcome you to our virtual booth covering the Winter Congress season. Here you can learn about Nektar’s cancer research and development activities and our mission to harness the immune system in the fight against cancer.
Please click on the thumbnails below to access the PDFs of the documents
If you have any questions, please use the contact button on the right for more information.
Bempegaldesleukin (BEMPEG; NKTR-214):
Bempegaldesleukin (an investigational first-in-class CD122-preferential IL-2 pathway agonist) in combination with a checkpoint inhibitor, leverages two immuno-oncology pathways with the aim of addressing the unmet needs of patients living with cancer.
Skin Cancer (1L Metastatic Melanoma and Adjuvant Melanoma):
A phase 3, randomized, open-label study of bempegaldesleukin (BEMPEG; NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients with previously untreated, unresectable or metastatic melanoma
Bladder Cancer (1L Metastatic Urothelial Carcinoma (mUC) and Muscle Invasive Bladder Cancer (MIBC)):
Kidney Cancer (1L Advanced Renal Cell Carcinoma (RCC)):
Lung Cancer (1L Non-Small Cell Lung Cancer (NSCLC)):
NKTR-255 is an investigational IL-15 agonist that is designed to engage the IL-15 pathway to increase both NK cell proliferation and activation and proliferation and survival of CD8+ T cells.
Multiple Myeloma and Non-Hodgkin's Lymphoma:
NKTR-262 is an investigational novel small molecule agonist designed to activate toll-like receptors (TLR 7/8), promoting TLR activation to induce the generation of antigen-specific cytotoxic T cells to the patient’s specific tumor.
Various Locally Advanced and Metastatic Tumors:
Interleukin-2 (IL-2) Review
This publication includes safety, tolerability, and clinical activity from the PIVOT-02, a single-arm, Phase I dose-escalation trial (NCT02983045), treatment with the CD122-preferential IL-2 pathway agonist bempegaldesleukin plus nivolumab in patients with immunotherapy-naïve advanced solid tumors, including melanoma, renal cell carcinoma, and non-small cell lung cancer.
Selection of the recommended phase 2 dose (RP2D) of NKTR-262 in combination with bempegaldesleukin in REVEAL (NCT03435640), a phase 1/2, open-label, multicenter, dose escalation and expansion study of NKTR-262 in combination with bempegaldesleukin with and without nivolumab in patients with advanced solid tumors.